126370-67-0

Basic information

• Product Name: 6-PHENYL-3-PYRIDINAMINE
• Synonyms: 6-PHENYL-3-PYRIDINAMINE;6-Phenylpyrid-3-ylamine;6-PHENYL-PYRIDIN-3-YLAMINE;6-PHENYLPYRIDINE-3-AMINE;5-AMINO-2-PHENYLPYRIDINE;6-Phenylpyridin-3-amine, (5-Aminopyridin-2-yl)benzene
• CAS NO: 126370-67-0
• Molecular Formula: C₁₁H₁₀N₂
• Molecular Weight: 170.21
• Mol File: 126370-67-0.mol

Chemical Properties

• Melting Point: 103 °C
• Boiling Point: 341.9 °C at 760 mmHg
• Flash Point: 187.3 °C
• Appearance: /
• Density: 1.133 g/cm³
• Vapor Pressure: 7.82E-05mmHg at 25°C
• Refractive Index: 1.625
• Storage Temp.: 2-8°C
• PKA: 5.37±0.10(Predicted)
• CAS DataBase Reference: 6-PHENYL-3-PYRIDINAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-PHENYL-3-PYRIDINAMINE(126370-67-0)
• EPA Substance Registry System: 6-PHENYL-3-PYRIDINAMINE(126370-67-0)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36
• HazardClass: IRRITANT
• Hazardous Substances Data: 126370-67-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Phenyl-3-pyridinamine is used as an intermediate in the synthesis of various pharmaceuticals for its unique structural properties that facilitate the creation of new drug molecules.
Used in Organic Compounds Synthesis:
6-PHENYL-3-PYRIDINAMINE is utilized as a key component in the synthesis of a range of organic compounds, leveraging its reactivity and structural features to produce desired outcomes in chemical reactions.
Used in Dye Production:
6-Phenyl-3-pyridinamine is employed in the production of dyes, where its chemical structure contributes to the color and properties of the final product.

InChI:InChI=1/C11H10N2/c12-10-6-7-11(13-8-10)9-4-2-1-3-5-9/h1-8H,12H2

Upstream product

• 5350-93-6 6-Chloro-pyridin-3-ylamine 
• 98-80-6 phenylboronic acid 
• 30091-51-1 5-benzoyl-2-phenylpyridine 
• 780-69-8 triethoxyphenylsilane 
• 13534-97-9 6-bromopyridine-3-amine 
• 71-43-2 benzene 
• 4548-45-2 2-chloro-5-nitropyridine 
• 5418-51-9 5-nitro-2-hydroxypyridine 
• 89076-64-2 3-nitro-6-phenylpyridine 
• 58088-38-3 phenyl-(6-phenyl-[3]pyridyl)-ketone-(E)-oxime 

Downstream Products

• 508219-81-6 5-hydrazino-2-phenylpyridine hydrochloride 
• 898568-39-3 2-Bromo-6-phenylpyridin-3-amine 
• 1187890-26-1 N-(6-phenyl-pyridin-3-yl)-malonamic acid ethyl ester 
• 1332586-74-9 4-cyano-N-(6-phenylpyridin-3-yl)benzamide 
• 1332586-73-8 N-(6-phenylpyridin-3-yl)-4-sulfamoylbenzamide 
• 1357164-10-3 4-amino-3-(6-phenylpyridine-3-ylazo)naphthalene-1-sulfonic acid sodium salt 
• 1357165-44-6 C₁₁H₈N₃⁽¹⁺⁾*Cl^(1-) 
• 1164113-30-7 C₁₈H₁₄N₂O₂ 
• 1187889-77-5 3-oxo-N-(6-phenyl-pyridin-3-yl)-3-[4-(3,4,5-trifluoro-benzoyl)-piperazin-1-yl]-propionamide 
• 1187889-75-3 3-oxo-N-(6-phenyl-pyridin-3-yl)-3-[4-(2-trifluoromethyl-benzoyl)-piperazin-1-yl]-propionamide 
• 1188372-61-3 3-[4-(2-chloro-phenoxy)-piperidin-1-yl]-3-oxo-N-(6-phenyl-pyridin-3-yl)-propionamide 
• 1188372-59-9 3-[4-(2-chloro-5-fluoro-phenoxy)-piperidin-1-yl]-3-oxo-N-(6-phenyl-pyridin-3-yl)-propionamide 

Relevant articles and documents

NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS

The present invention relates to novel benzamides derivatives of formula (I) as modulators of PPAR-gamma receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of PPAR-gamma receptor, such as cancer; metabolic diseases, inflammatory diseases, respiratory disorders, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases and renal diseases.

METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

Pd-Catalyzed Suzuki coupling reactions of aryl halides containing basic nitrogen centers with arylboronic acids in water in the absence of added base

The Pd-catalyzed Suzuki coupling reactions of a series of aryl chlorides and aryl bromides containing basic nitrogen centers with arylboronic acids in water in the absence of added base are reported. The reactions proceed either partially or entirely under acidic conditions. After surveying twenty-two phosphorus ligands, high yields of products were obtained with aryl chlorides only when a bulky ligand, 2-(di-tert-butyl-phosphino)-1-phenyl-1H-pyrrole (cataCXiumPtB) was used. In contrast, aryl bromides produced high yields of products in the absence of both added base and added ligand. In order to explore the Suzuki coupling process entirely under acidic conditions, a series of reactions were conducted in buffered acidic media using several model substrates. 4-Chlorobenzylamine, in the presence of cataCXiumPtB, produced high yields of product at buffered pH 6.0; the yields dropped off precipitously at buffered pH 5.0 and lower. The fall-off in yield was attributed to the decomposition of the Pd-ligand complex due to the protonation of the ligand in the more acidic aqueous media. In contrast, in the absence of an added ligand, 4-amino-2-chloropyridine produced quantitative yields at buffered pH 3.5 and 4.5 while 4-amino-2-bromopyridine produced quantitative yields in a series of buffered media ranging from pH 4.5 to 1.5. These substrates are only partially protonated in acidic media and can behave as active Pd ligands in the Suzuki catalytic cycle.

A novel graphene-supported palladium catalyst for suzuki-miyaura coupling of less reactive heteroaryl halides in water

An efficient reduced graphene oxide-supported heterogenized palladium complex with pyrene-tagged ketoiminato ligand has been developed and used for cross-coupling of less reactive heteroaryl halides in water. Desirable catalytic activity was observed with high (up to 98%) conversion of the less reactive reactants under relatively mild conditions. The efficiency and green nature of the catalyst were confirmed without significant loss of activity.

POPd/TBAB co-catalyzed Suzuki cross-coupling reaction of heteroaryl chlorides/bromides with 4-fluorophenylboronic acid in water

An organic solvent free and efficient heterogeneous synthesis for bridging heteroaryl halides and 4-fluorophenylboronic acid was studied in aqueous media according to the Suzuki cross-coupling protocol. High yields of heteroaryl-aryl fluorides were successfully obtained with: chloro-/bromo-substituted pyridine, thiophene, indole, and inzole in neat water using palladium phosphinous acid complexes (POPd)/tetrabutylammonium bromide (TBAB) as co-catalysts. A possible mechanism for the heterogeneous coupling reaction is proposed and discussed according to the function of the TBAB interphases. The notable properties of the reported method are highly co-catalytic activity, hetero-atom tolerance, simple separating procedure and little environmental disposal impact.

5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Structure-activity relationship study of E6 as a novel necroptosis inducer

Necroptosis inducers represent a promising potential treatment for drug-resistant cancer. We herein describe the structure modification of E6, which was identified recently as a potent and selective necroptosis inducer. The studies described herein demonstrate for the first time that functionalized biphenyl derivatives possess necroptosis inducer activity. Furthermore, these studies have led to the identification of two promising compounds (5h and 5j) that can be used for further optimization studies as well as mechanism of action investigations.

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Vasicine catalyzed direct C-H arylation of unactivated arenes: Organocatalytic application of an abundant alkaloid

Vasicine, a quinazoline alkaloid isolated from Adhatoda vasica, has been employed as an organocatalyst for direct C-H arylation of unactivated arenes with aryl iodides/bromides without the assistance of any transition metal catalyst. A number of sensitive functional groups such as methyl, methoxy, O-benzyl, acetyl, and amino were well tolerated under present reaction conditions. Mechanistic investigation supported the involvement of radical intermediates.

NAPHTHALENE DERIVATIVE

The present invention provides compounds which can regulate VCP activity. The present invention provides the compound of formula (I) (R is as defined in the description) or oxides, esters, prodrugs, pharmaceutically acceptable salts or solvates thereof. The compounds can regulate VCP activity, and thus are useful for treating VCP-mediated diseases such as neurodegenerative diseases.